Roth Capital Reiterates Buy On MacroGenics, Sees 36% Upside
In a report released this morning, Roth Capital analyst Debjit Chattopadhyay reiterated coverage on MacroGenics, Inc. (MGNX) with a Buy rating and a $30.00 price target, which represents a potential upside of 36% from where the stock is currently trading.
“MacroGenics is pioneering immune-modulation-based therapies through its ability to engineer antibodies at the molecular level. With the recent addition of a DART-based compound to its clinical-stage pipeline, MacroGenics has formally entered the multi-target engagement race. We anticipate up to six (currently three) new compounds in the clinic by the end of 2015, spanning both solid and liquid tumors providing multiple shots on goal”, Chattopadhyay noted.